Skip to content

Castellum CTM Proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs

Proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs at other companies

Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$0
Arvinas logo
ArvinasARVN
$0
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$18.15M-19.9%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$81.01M-28.0%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$0-100%
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
$0-100%

Other financials

Income statement

See full
Revenue$14.3M+22.5%
Gross profit$5.1M+11.1%
Operating income-$698.0K+53.0%
Net income-$351.3K+70.0%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$15.8M+18.7%
Total debt$738.3K-29.9%
Total equity$36.1M+38.5%
Total assets$41.8M+1.7%

Cash flow

See full
Operating cash flow$1.3M+152%
CapEx$9.7K
Free cash flow$1.3M+151%

Valuation

See full
Market cap$68.17M-31.6%
Enterprise value$53.14M-38.5%
P/S1.2×-0.9×

Profitability

See full
Gross margin35.8%-4.8pp
Operating margin-3.7%-1.5pp
Net margin-2.8%-1.3pp
FCF margin-3.7%

Returns & leverage

See full
Return on equity-5.1%-2.3pp
Debt / equity0.0×
Current ratio4.8×+1.9×

Where this comes from

Reported directly by Castellum in its filing.

Tagged under the XBRL concept ctm:ProceedsFromIssuanceOfPreferredAndCommonStock.

The official record: Castellum’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castellum's proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castellum's proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs?
Castellum (CTM) reported proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs of $0 in Q1 2026.
How has Castellum's proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs changed year-over-year?
Castellum's proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs decreased by 100.0% year-over-year, from $5.93M to $0.
What does proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs mean?
Reflects the net cash inflows received from the issuance of equity securities, including common stock, preferred stock, and warrants, after deducting issuance costs. It serves as a primary indicator of the company's ability to raise external capital to fund operations, acquisitions, or debt repayment.